Welcome to Markets Desk, here's what's moving.
Intuit reaffirmed its first quarter and full fiscal twenty twenty seven guidance Thursday, a notable signal of confidence from one of fintech's heaviest hitters. In a market hungry for forward visibility, a company standing behind its numbers carries real weight with institutional investors watching the software sector closely.
Shifting to healthcare, AbbVie announced it will present full Phase three results for Etentamig, its investigational bispecific T-cell engager targeting multiple myeloma, at the International Myeloma Society's annual meeting in Glasgow this September. Positive late-stage data in oncology can be a meaningful catalyst, and all eyes will be on those efficacy and safety readouts when they hit the floor.
And on the Medicare front, open enrollment is now just one month out, a reminder that millions of Americans are about to make consequential decisions about their coverage. Advisors are urging beneficiaries to review current plans now, before the window opens, given ongoing shifts in formularies and premium structures across both Medicare Advantage and Part D.
That's the tape. Markets Desk, signing off the floor.
